This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2024
AMA 2024
ASCO 2024
AUA 2024
APCCC 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO 2024
ASCO 2024 Bladder Cancer
ASCO 2024
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Upper Tract Urothelial Carcinoma
Press Releases
ASCO 2024 Bladder Cancer
Viewing 281-300 of 11487 articles
AUA 2024: mCRPC: Key Updates in Radioligand Therapy, PSMA Sensitive Disease
AUA 2024: Whitmore Lecture – Optimizing Outcomes in High-Risk Localized Prostate Cancer – Cure is Possible when Cure is Necessary.
AUA 2024: First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab and Nab-Paclitaxel Followed by Postsurgical Adjuvant NIVO in Patients with Muscle-Invasive Bladder Cancer
AUA 2024: Panel Discussion: Artificial Intelligence
AUA 2024: Outcomes of Minimally Invasive Nephrectomy Following Immune-Checkpoint Inhibitor Therapy: Data from a Multicenter Study
AUA 2024: Panel Discussion: Obstructive Pyelonephritis Due to Ureteral Stone
AUA 2024: Response to Primary Chemoablation With UGN-102 in Patients with New or Recurrent LG IR NMIBC: Post-hoc Analysis of the ATLAS Trial
AUA 2024: Genomic Signatures Associated with Adverse Pathologic Features at Radical Prostatectomy Among Active Surveillance Eligible Men
AUA 2024: High Decipher Score Defines the Subgroup Most at Risk of Metastatic Progression Among Patients with Lower Grade Tumors Classified as NCCN High-Risk Based on Elevated Prostate-Specific Antigen Level Alone
AUA 2024: Comparing Methocarbamol to Oxybutynin for Stent Colic – A Prospective Randomized Controlled Trial
AUA 2024: First Prospective Clinical Assessment of The ILY Robotic Flexible Ureteroscopy Platform.
AUA 2024: Automated Renal Volume Measurement using Artificial Intelligence: Correlation to Post-Operative Renal Function after Radical and Partial Nephrectomy
AUA 2024: Journal of Urology Lecture: Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of Color
AUA 2024: Development and External Validation of an Artificial Intelligence-Based Tool for PROGression Risk Assessment in Non-Muscle Invasive Bladder Cancer (PROGRxN-BCa)
AUA 2024: Comprehensive Evaluation of Response to Immune Checkpoint Blockade in Primary Tumor: Radiographic and Radiomic Features Predict Pathologic Response in Primary Tumor
AUA 2024: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC): Phase 3 Preliminary Results
AUA 2024: Computer Vision Analysis of Upper Tract Urothelial Carcinoma to Predict High vs Low Grade Pathology
AUA 2024: Development and Validation of Generalizable Interpretable AI Biomarkers to Predict Clinical Outcomes in BCG-Treated Patients with Non-Muscle Invasive Bladder Cancer
AUA 2024: Survival is Dramatically Improved for mRCC Patients with Sarcomatoid Features who are Treated with Cytoreductive Nephrectomy and Immune Checkpoint Inhibitors Regardless of Treatment Sequence
AUA 2024: Tumor Size Reduction (≥10% ) Resulting from Pre-Surgical Systemic Therapy Predicts Improved Survival Following Cytoreductive Nephrectomy
10
11
12
13
14
15
16
17
18
19
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
